Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 15 | 2020 | 460 | 2.570 |
Why?
|
| Polyglycolic Acid | 14 | 2015 | 48 | 2.450 |
Why?
|
| Lactic Acid | 14 | 2015 | 112 | 2.330 |
Why?
|
| Drug Carriers | 13 | 2015 | 174 | 2.160 |
Why?
|
| Drug Delivery Systems | 14 | 2020 | 277 | 1.970 |
Why?
|
| Polymers | 9 | 2015 | 155 | 1.640 |
Why?
|
| Radiation-Protective Agents | 5 | 2016 | 14 | 1.590 |
Why?
|
| Drug Compounding | 19 | 2024 | 93 | 1.420 |
Why?
|
| Amifostine | 6 | 2008 | 9 | 1.410 |
Why?
|
| Chromones | 8 | 2023 | 53 | 1.380 |
Why?
|
| RNA, Small Interfering | 5 | 2017 | 436 | 1.240 |
Why?
|
| Particle Size | 18 | 2017 | 272 | 1.080 |
Why?
|
| Polyglactin 910 | 5 | 2015 | 10 | 1.000 |
Why?
|
| Drug Stability | 15 | 2024 | 129 | 0.980 |
Why?
|
| Excipients | 7 | 2022 | 25 | 0.950 |
Why?
|
| Chitosan | 4 | 2010 | 53 | 0.930 |
Why?
|
| Administration, Oral | 16 | 2024 | 260 | 0.880 |
Why?
|
| Surface-Active Agents | 4 | 2014 | 46 | 0.880 |
Why?
|
| Chemistry, Pharmaceutical | 9 | 2015 | 97 | 0.870 |
Why?
|
| Gene Silencing | 3 | 2017 | 154 | 0.860 |
Why?
|
| Capsules | 10 | 2008 | 28 | 0.860 |
Why?
|
| Suspensions | 12 | 2024 | 48 | 0.730 |
Why?
|
| Chromatography, High Pressure Liquid | 13 | 2024 | 465 | 0.650 |
Why?
|
| Liposomes | 6 | 2020 | 132 | 0.630 |
Why?
|
| Technology, Pharmaceutical | 5 | 2015 | 35 | 0.620 |
Why?
|
| Biocompatible Materials | 4 | 2011 | 108 | 0.610 |
Why?
|
| Insulin | 2 | 2015 | 258 | 0.600 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 108 | 0.590 |
Why?
|
| Microscopy, Electron, Scanning | 10 | 2015 | 159 | 0.580 |
Why?
|
| Pentamidine | 4 | 2004 | 11 | 0.570 |
Why?
|
| Fenretinide | 2 | 2015 | 9 | 0.570 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 1019 | 0.560 |
Why?
|
| Solubility | 11 | 2015 | 139 | 0.530 |
Why?
|
| Osteosarcoma | 1 | 2017 | 30 | 0.520 |
Why?
|
| Chromans | 1 | 2016 | 16 | 0.510 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 49 | 0.510 |
Why?
|
| Clindamycin | 1 | 2016 | 13 | 0.500 |
Why?
|
| Vitamin E | 1 | 2016 | 62 | 0.500 |
Why?
|
| Mebendazole | 1 | 2015 | 4 | 0.470 |
Why?
|
| Squalene | 1 | 2015 | 4 | 0.470 |
Why?
|
| Tubulin Modulators | 1 | 2015 | 20 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 220 | 0.450 |
Why?
|
| Drug Storage | 7 | 2023 | 28 | 0.440 |
Why?
|
| Fatty Acids | 1 | 2015 | 134 | 0.430 |
Why?
|
| Micelles | 1 | 2014 | 36 | 0.420 |
Why?
|
| Coumarins | 2 | 2011 | 45 | 0.420 |
Why?
|
| Molecular Imaging | 1 | 2014 | 30 | 0.420 |
Why?
|
| Delayed-Action Preparations | 5 | 2008 | 74 | 0.410 |
Why?
|
| Buprenorphine | 2 | 2007 | 51 | 0.400 |
Why?
|
| Nanostructures | 3 | 2013 | 161 | 0.400 |
Why?
|
| Nanocapsules | 2 | 2010 | 19 | 0.400 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 184 | 0.400 |
Why?
|
| Skin Absorption | 1 | 2013 | 16 | 0.400 |
Why?
|
| Lipids | 3 | 2013 | 256 | 0.390 |
Why?
|
| Calorimetry, Differential Scanning | 5 | 2015 | 35 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 432 | 0.380 |
Why?
|
| Propranolol | 2 | 2010 | 18 | 0.380 |
Why?
|
| Mice | 14 | 2016 | 6644 | 0.370 |
Why?
|
| Vaccines | 1 | 2013 | 65 | 0.370 |
Why?
|
| Freeze Drying | 1 | 2011 | 29 | 0.360 |
Why?
|
| RNA Stability | 1 | 2011 | 28 | 0.360 |
Why?
|
| Liver | 2 | 2012 | 511 | 0.360 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 51 | 0.350 |
Why?
|
| Biodegradation, Environmental | 6 | 2006 | 82 | 0.340 |
Why?
|
| Solvents | 4 | 2008 | 113 | 0.330 |
Why?
|
| RNA Interference | 1 | 2011 | 247 | 0.330 |
Why?
|
| Emulsions | 5 | 2016 | 36 | 0.330 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2010 | 2 | 0.320 |
Why?
|
| Genetic Vectors | 1 | 2010 | 165 | 0.320 |
Why?
|
| Cell Line, Tumor | 8 | 2020 | 2676 | 0.310 |
Why?
|
| Cellulose | 1 | 2010 | 24 | 0.310 |
Why?
|
| Fluorescence | 1 | 2010 | 118 | 0.310 |
Why?
|
| Antifungal Agents | 3 | 2000 | 169 | 0.310 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 539 | 0.310 |
Why?
|
| Serum Albumin, Bovine | 3 | 2013 | 49 | 0.310 |
Why?
|
| Mercaptoethylamines | 1 | 2008 | 1 | 0.290 |
Why?
|
| Animals | 17 | 2020 | 16992 | 0.290 |
Why?
|
| Apolipoproteins E | 3 | 2016 | 138 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 146 | 0.280 |
Why?
|
| Indomethacin | 1 | 2008 | 25 | 0.280 |
Why?
|
| Glycolates | 2 | 2007 | 6 | 0.280 |
Why?
|
| Cell Survival | 4 | 2017 | 945 | 0.270 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 1723 | 0.270 |
Why?
|
| Polyvinyl Alcohol | 3 | 2002 | 7 | 0.270 |
Why?
|
| Transfection | 4 | 2013 | 532 | 0.270 |
Why?
|
| Hepacivirus | 3 | 2012 | 74 | 0.260 |
Why?
|
| DNA | 1 | 2010 | 592 | 0.260 |
Why?
|
| Zidovudine | 2 | 1996 | 32 | 0.250 |
Why?
|
| Spectrophotometry, Ultraviolet | 3 | 2015 | 104 | 0.250 |
Why?
|
| Humans | 23 | 2023 | 43102 | 0.250 |
Why?
|
| Enkephalin, Leucine | 1 | 2006 | 4 | 0.240 |
Why?
|
| Permeability | 3 | 2015 | 67 | 0.240 |
Why?
|
| Diabetic Retinopathy | 2 | 2016 | 78 | 0.230 |
Why?
|
| Hydrogels | 2 | 2002 | 59 | 0.220 |
Why?
|
| Viscosity | 4 | 2017 | 46 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 92 | 0.220 |
Why?
|
| Clonidine | 1 | 2024 | 50 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2020 | 388 | 0.210 |
Why?
|
| Surface Properties | 3 | 2010 | 160 | 0.210 |
Why?
|
| Lactose | 2 | 2016 | 16 | 0.200 |
Why?
|
| Azathioprine | 1 | 2023 | 5 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 694 | 0.200 |
Why?
|
| Tablets | 2 | 2009 | 14 | 0.200 |
Why?
|
| Malaria, Falciparum | 2 | 2015 | 90 | 0.200 |
Why?
|
| Kinetics | 4 | 2015 | 695 | 0.190 |
Why?
|
| Plasmodium falciparum | 2 | 2015 | 144 | 0.190 |
Why?
|
| Amitriptyline | 1 | 2022 | 9 | 0.190 |
Why?
|
| Retina | 2 | 2016 | 289 | 0.180 |
Why?
|
| Temperature | 2 | 2016 | 313 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2016 | 307 | 0.180 |
Why?
|
| Protamines | 2 | 2011 | 21 | 0.170 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2014 | 184 | 0.170 |
Why?
|
| Administration, Inhalation | 2 | 2015 | 92 | 0.170 |
Why?
|
| Metronidazole | 1 | 2021 | 16 | 0.170 |
Why?
|
| Miconazole | 1 | 2000 | 4 | 0.170 |
Why?
|
| Methylene Chloride | 3 | 2008 | 6 | 0.170 |
Why?
|
| Gelatin | 1 | 2020 | 17 | 0.170 |
Why?
|
| Hydrocortisone | 1 | 2021 | 93 | 0.170 |
Why?
|
| Allopurinol | 1 | 2020 | 13 | 0.170 |
Why?
|
| Hepatitis C | 2 | 2012 | 139 | 0.160 |
Why?
|
| Uric Acid | 1 | 2020 | 29 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 51 | 0.160 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 22 | 0.160 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 287 | 0.160 |
Why?
|
| Amlodipine | 1 | 2019 | 20 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2020 | 97 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2011 | 411 | 0.150 |
Why?
|
| Carbon | 1 | 2020 | 128 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 4 | 0.150 |
Why?
|
| Naltrexone | 1 | 2019 | 34 | 0.150 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 6 | 0.150 |
Why?
|
| Caco-2 Cells | 2 | 2015 | 64 | 0.140 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2008 | 22 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 131 | 0.140 |
Why?
|
| Sulfadiazine | 1 | 2017 | 4 | 0.140 |
Why?
|
| Trimethoprim | 1 | 2017 | 6 | 0.140 |
Why?
|
| Biological Availability | 2 | 2008 | 116 | 0.130 |
Why?
|
| Acute Radiation Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 760 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2010 | 240 | 0.130 |
Why?
|
| Spironolactone | 1 | 2017 | 36 | 0.130 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 10 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2016 | 389 | 0.120 |
Why?
|
| Molecular Weight | 2 | 2009 | 168 | 0.120 |
Why?
|
| Leucine | 1 | 2016 | 31 | 0.120 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 51 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2016 | 42 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 508 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 62 | 0.120 |
Why?
|
| Water | 1 | 1998 | 316 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 1999 | 195 | 0.120 |
Why?
|
| Microspheres | 3 | 2001 | 49 | 0.120 |
Why?
|
| Neoplasms | 1 | 2007 | 1377 | 0.120 |
Why?
|
| Poloxamer | 1 | 2015 | 13 | 0.120 |
Why?
|
| Transition Temperature | 1 | 2015 | 9 | 0.120 |
Why?
|
| Malaria Vaccines | 1 | 2015 | 21 | 0.110 |
Why?
|
| Esters | 1 | 2015 | 25 | 0.110 |
Why?
|
| Intestinal Absorption | 1 | 2015 | 22 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2012 | 20 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2012 | 33 | 0.110 |
Why?
|
| Povidone | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 223 | 0.110 |
Why?
|
| Artemisinins | 1 | 2014 | 19 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 134 | 0.110 |
Why?
|
| Solutions | 1 | 2014 | 65 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 280 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 518 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 160 | 0.100 |
Why?
|
| Time Factors | 2 | 2011 | 1857 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 2015 | 191 | 0.100 |
Why?
|
| Antimalarials | 1 | 2014 | 64 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 140 | 0.100 |
Why?
|
| Cholesterol | 2 | 2012 | 232 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2013 | 25 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 259 | 0.100 |
Why?
|
| Plasmids | 2 | 2013 | 244 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 48 | 0.100 |
Why?
|
| Hela Cells | 1 | 2014 | 376 | 0.100 |
Why?
|
| Virus Replication | 2 | 2012 | 318 | 0.090 |
Why?
|
| Male | 6 | 2016 | 23409 | 0.090 |
Why?
|
| Mutation | 1 | 2017 | 1177 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2013 | 126 | 0.090 |
Why?
|
| Sonication | 1 | 2011 | 14 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 131 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2011 | 43 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 67 | 0.090 |
Why?
|
| Hepatocytes | 1 | 2011 | 80 | 0.090 |
Why?
|
| Glucose | 1 | 2012 | 244 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 152 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 256 | 0.080 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 154 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2012 | 321 | 0.080 |
Why?
|
| Pressure | 1 | 2010 | 50 | 0.080 |
Why?
|
| Eye | 1 | 2011 | 77 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 53 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2011 | 176 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 139 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2011 | 195 | 0.080 |
Why?
|
| Thiazoles | 1 | 2010 | 76 | 0.080 |
Why?
|
| Biological Transport | 1 | 2010 | 204 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2012 | 329 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 372 | 0.080 |
Why?
|
| Sodium Bicarbonate | 1 | 2009 | 7 | 0.070 |
Why?
|
| Jejunum | 1 | 2008 | 7 | 0.070 |
Why?
|
| Citric Acid | 1 | 2009 | 15 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2008 | 35 | 0.070 |
Why?
|
| Administration, Rectal | 1 | 2008 | 18 | 0.070 |
Why?
|
| Polyesters | 2 | 1999 | 28 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 36 | 0.070 |
Why?
|
| Cytoprotection | 1 | 2008 | 36 | 0.070 |
Why?
|
| Child | 3 | 2021 | 3443 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2008 | 35 | 0.070 |
Why?
|
| Cations | 1 | 2008 | 50 | 0.070 |
Why?
|
| Survival Rate | 1 | 2008 | 355 | 0.070 |
Why?
|
| Polysorbates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Stem Cells | 1 | 2008 | 152 | 0.070 |
Why?
|
| Gels | 1 | 2007 | 45 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 14 | 0.060 |
Why?
|
| Materials Testing | 1 | 2006 | 101 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 186 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 54 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1124 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 47 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2006 | 229 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 79 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1455 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2016 | 883 | 0.050 |
Why?
|
| Biotransformation | 1 | 2004 | 69 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 233 | 0.050 |
Why?
|
| Cattle | 1 | 2005 | 498 | 0.050 |
Why?
|
| Female | 4 | 2020 | 24698 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2000 | 8 | 0.040 |
Why?
|
| Freezing | 1 | 2000 | 17 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 1869 | 0.040 |
Why?
|
| Absorbable Implants | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pneumocystis | 1 | 1999 | 1 | 0.040 |
Why?
|
| Acetone | 1 | 1999 | 7 | 0.040 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1999 | 15 | 0.040 |
Why?
|
| Methanol | 1 | 1999 | 22 | 0.040 |
Why?
|
| Acetates | 1 | 1999 | 32 | 0.040 |
Why?
|
| Metoprolol | 1 | 1998 | 3 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 4 | 0.040 |
Why?
|
| Captopril | 1 | 1998 | 6 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 62 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 54 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 55 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 104 | 0.030 |
Why?
|
| Leukostasis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Blood-Retinal Barrier | 1 | 2016 | 11 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2016 | 8 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2016 | 7 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2016 | 29 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2016 | 36 | 0.030 |
Why?
|
| Ethanol | 1 | 1999 | 224 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 54 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 76 | 0.030 |
Why?
|
| Aspirin | 1 | 1996 | 89 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 94 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2014 | 66 | 0.030 |
Why?
|
| United States | 1 | 2005 | 5205 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 63 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 94 | 0.030 |
Why?
|
| DNA, Circular | 1 | 2013 | 8 | 0.020 |
Why?
|
| Replicon | 1 | 2012 | 7 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 129 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2012 | 22 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 209 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 183 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2011 | 19 | 0.020 |
Why?
|
| Dipeptides | 1 | 2011 | 31 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 278 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1081 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 263 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 6081 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 8214 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 655 | 0.020 |
Why?
|